Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 11, 2013 - Issue 9
Submit an article Journal homepage
50
Views
0
CrossRef citations to date
0
Altmetric
Theme: Inflammation & Infection of the Heart - Review

Cardiovascular involvements in HIV-infected patients

Rami AlharethiIntermountain Medical Center, Salt Lake City, UT, [email protected]
Pages 1227-1235 | Published online: 10 Jan 2014

References

  • Hogg R, Lima V, Sterne JA et al.; Antiretroviral Therapy Cohort C. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372(9635), 293–299 (2008).
  • Gill J, May M, Lewden C et al.; Antiretroviral Therapy Cohort C. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin. Infect. Dis. 50(10), 1387–1396 (2010).
  • Currier JS, Lundgren JD, Carr A et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 118(2), e29–e35 (2008).
  • Currier JS, Taylor A, Boyd F et al. Coronary heart disease in HIV-infected individuals. J. Acquir. Immune. Defic. Syndr. 33(4), 506–512 (2003).
  • Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J. Clin. Endocrinol. Metab. 92(7), 2506–2512 (2007).
  • Kaplan RC, Kingsley LA, Sharrett AR et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin. Infect. Dis. 45(8), 1074–1081 (2007).
  • Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74(5), 1045–1052 (1992).
  • Mujawar Z, Rose H, Morrow MP et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 4(11), e365 (2006).
  • Dube MP, Cadden JJ. Lipid metabolism in treated HIV Infection. Best Pract. Res. Clin. Endocrinol. Metab. 25(3), 429–442 (2011).
  • Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS 11(7), 938–939 (1997).
  • Mobius U, Lubach-Ruitman M, Castro-Frenzel B et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J. Acquir. Immune Defic. Syndr. 39(2), 174–180 (2005).
  • Fontas E, Van Leth F, Sabin CA et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J. Infect. Dis. 189(6), 1056–1074 (2004).
  • Crane HM, Grunfeld C, Willig JH et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS 25(2), 185–195 (2011).
  • Butt AA, Mcginnis K, Rodriguez-Barradas MC et al. HIV infection and the risk of diabetes mellitus. AIDS 23(10), 1227–1234 (2009).
  • Brown TT, Cole SR, Li X et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch. Intern. Med. 165(10), 1179–1184 (2005).
  • Tien PC, Schneider MF, Cole SR et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 21(13), 1739–1745 (2007).
  • Rudich A, Ben-Romano R, Etzion S, Bashan N. Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. Acta Physiol. Scand. 183(1), 75–88 (2005).
  • Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am. J. hypertens. 7(7 Pt 2), 7S–12S (1994).
  • Seaberg EC, Munoz A, Lu M et al.Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 19(9), 953–960 (2005).
  • Rosendorff C, Black HR, Cannon CP et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 115(21), 2761–2788 (2007).
  • Group DaDS, Friis-Moller N, Reiss P et al. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 356(17), 1723–1735 (2007).
  • Helleberg M, Afzal S, Kronborg G et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin. Infect. Dis. 56(5), 727–734 (2013).
  • Silva-Cardoso J, Moura B, Martins L, Mota-Miranda A, Rocha-Goncalves F, Lecour H. Pericardial involvement in human immunodeficiency virus infection. Chest 115(2), 418–422 (1999).
  • Heidenreich PA, Eisenberg MJ, Kee LL et al. Pericardial effusion in AIDS. Incidence and survival. Circulation 92(11), 3229–3234 (1995).
  • De Castro S, Migliau G, Silvestri A et al. Heart involvement in AIDS: a prospective study during various stages of the disease. Eur. Heart J. 13(11), 1452–1459 (1992).
  • Himelman RB, Chung WS, Chernoff DN, Schiller NB, Hollander H. Cardiac manifestations of human immunodeficiency virus infection: a two-dimensional echocardiographic study. J. Am. Coll. Cardiol. 13(5), 1030–1036 (1989).
  • Corallo S, Mutinelli MR, Moroni M et al. Echocardiography detects myocardial damage in AIDS: prospective study in 102 patients. Eur. Heart J. 9(8), 887–892 (1988).
  • Lind A, Reinsch N, Neuhaus K et al. Pericardial effusion of HIV-infected patients? Results of a prospective multicenter cohort study in the era of antiretroviral therapy. Eur. J. Med. Res. 16(11), 480–483 (2011).
  • Chen Y, Brennessel D, Walters J, Johnson M, Rosner F, Raza M. Human immunodeficiency virus-associated pericardial effusion: report of 40 cases and review of the literature. Am. Heart J. 137(3), 516–521 (1999).
  • Lipshultz SE, Fisher SD, Lai WW, Miller TL. Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS 17( Suppl. 1), S96–S122 (2003).
  • Sliwa K, Carrington MJ, Becker A, Thienemann F, Ntsekhe M, Stewart S. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. Eur. Heart J. 33(7), 866–874 (2012).
  • Currie PF, Jacob AJ, Foreman AR, Elton RA, Brettle RP, Boon NA. Heart muscle disease related to HIV infection: prognostic implications. BMJ 309(6969), 1605–1607 (1994).
  • Anderson DW, Virmani R, Reilly JM et al. Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome. J. Am. Coll. Cardiol. 11(4), 792–799 (1988).
  • Fisher SD, Lipshultz SE. Epidemiology of cardiovascular involvement in HIV disease and AIDS. Ann. N. Y. Acad. Sci. 946, 13–22 (2001).
  • Sudano I, Spieker LE, Noll G, Corti R, Weber R, Luscher TF. Cardiovascular disease in HIV infection. Am. Heart J. 151(6), 1147–1155 (2006).
  • Goldblum N, Daefler S, Llana T, Ablashi D, Josephs S, Salahuddin Z. Susceptibility to HIV-1 infection of a human B-lymphoblastoid cell line, DG75, transfected with subgenomic DNA fragments of Epstein-Barr virus. Dev. Biol. Stand. 72, 309–313 (1990).
  • Fisher SD, Bowles NE, Towbin JA, Lipshultz SE. Mediators in HIV-associated cardiovascular disease: a focus on cytokines and genes. AIDS 17( Suppl. 1), S29–S35 (2003).
  • Lewis W, Kohler JJ, Hosseini SH et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS 20(5), 675–684 (2006).
  • Lewis W, Grupp IL, Grupp G et al. Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine. Lab. Invest. 80(2), 187–197 (2000).
  • Dube MP, Lipshultz SE, Fichtenbaum CJ et al. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation 118(2), e36–e40 (2008).
  • Miller TL, Orav EJ, Colan SD, Lipshultz SE. Nutritional status and cardiac mass and function in children infected with the human immunodeficiency virus. Am. J. Clin. Nutr. 66(3), 660–664 (1997).
  • Abelmann WH, Lorell BH. The challenge of cardiomyopathy. J. Am. Coll. Cardiol. 13(6), 1219–1239 (1989).
  • Kavanaugh-Mchugh AL, Ruff A, Perlman E, Hutton N, Modlin J, Rowe S. Selenium deficiency and cardiomyopathy in acquired immunodeficiency syndrome. JPEN J. Parenter. Enteral Nutr. 15(3), 347–349 (1991).
  • Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 132(5), 1961–1970 (1993).
  • Neumann T, Reinsch N, Neuhaus K et al. [BNP in HIV-infected patients]. Herz 34(8), 634–640 (2009).
  • Duprez DA, Neuhaus J, Tracy R et al. N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients. AIDS 25(5), 651–657 (2011).
  • Leuchte HH, Holzapfel M, Baumgartner RA et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J. Am. Coll. Cardiol. 43(5), 764–770 (2004).
  • Lipshultz SE, Orav EJ, Sanders SP, Colan SD. Immunoglobulins and left ventricular structure and function in pediatric HIV infection. Circulation 92(8), 2220–2225 (1995).
  • Sims DB, Uriel N, Gonzalez-Costello J et al. Human immunodeficiency virus infection and left ventricular assist devices: a case series. J. Heart Lung Transplant. 30(9), 1060–1064 (2011).
  • Castel MA, Perez-Villa F, Miro JM. Heart transplantation in HIV-infected patients: more cases in Europe. J. Heart Lung Transplant. 30(12), 1418 (2011).
  • Calabrese LH, Albrecht M, Young J et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N. Engl. J. Med. 348(23), 2323–2328 (2003).
  • Uriel N, Jorde UP, Cotarlan V et al. Heart transplantation in human immunodeficiency virus-positive patients. J. Heart Lung Transplant. 28(7), 667–669 (2009).
  • Barbaro G, Fisher SD, Lipshultz SE. Pathogenesis of HIV-associated cardiovascular complications. Lancet Infect. Dis. 1(2), 115–124 (2001).
  • Lipshultz SE, Easley KA, Orav EJ et al. Cardiac dysfunction and mortality in HIV-infected children: the prospective P2C2 HIV multicenter study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 102(13), 1542–1548 (2000).
  • Ho JE, Hsue PY. Cardiovascular manifestations of HIV infection. Heart 95(14), 1193–1202 (2009).
  • Hsue PY, Giri K, Erickson S et al. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 109(3), 316–319 (2004).
  • Mehta NJ, Khan IA. HIV-associated coronary artery disease. Angiology 54(3), 269–275 (2003).
  • Lang S, Mary-Krause M, Cotte L et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch. Intern. Med. 170(14), 1228–1238 (2010).
  • Worm SW, Sabin C, Weber R et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J. Infect. Dis. 201(3), 318–330 (2010).
  • Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N. Engl. J. Med. 348(8), 702–710 (2003).
  • Stein JH, Klein MA, Bellehumeur JL et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104(3), 257–262 (2001).
  • Fu W, Chai H, Yao Q, Chen C. Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression. J. Acquir. Immune Defic. Syndr. 39(2), 152–158 (2005).
  • Baliga RS, Liu C, Hoyt DG, Chaves AA, Bauer JA. Vascular endothelial toxicity induced by HIV protease inhibitor: evidence of oxidant-related dysfunction and apoptosis. Cardiovasc. Toxicol. 4(2), 199–206 (2004).
  • Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database. J. Acquir. Immune Defic. Syndr. 57(3), 245–253 (2011).
  • Ribaudo HJ, Benson CA, Zheng Y et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin. Infect. Dis. 52(7), 929–940 (2011).
  • Ding X, Andraca-Carrera E, Cooper C et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J. Acquir. Immune Defic. Syndr. 61(4), 441–447 (2012).
  • , Strategies for Management of Antiretroviral Therapy Study GroupEmery S, Neuhaus JA, Phillips AN et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J. Infect. Dis. 197(8), 1133–1144 (2008).
  • Ovbiagele B, Nath A. Increasing incidence of ischemic stroke in patients with HIV infection. Neurology 76(5), 444–450 (2011).
  • Rasmussen LD, Engsig FN, Christensen H et al. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS 25(13), 1637–1646 (2011).
  • Tipping B, De Villiers L, Wainwright H, Candy S, Bryer A. Stroke in patients with human immunodeficiency virus infection. J. Neurol. Neurosurg. Psychiatry 78(12), 1320–1324 (2007).
  • Cole JW, Pinto AN, Hebel JR et al. Acquired immunodeficiency syndrome and the risk of stroke. Stroke 35(1), 51–56 (2004).
  • Benjamin LA, Bryer A, Emsley HC, Khoo S, Solomon T, Connor MD. HIV infection and stroke: current perspectives and future directions. Lancet Neurol. 11(10), 878–890 (2012).
  • Kumwenda JJ, Mateyu G, Kampondeni S, Van Dam AP, Van Lieshout L, Zijlstra EE. Differential diagnosis of stroke in a setting of high HIV prevalence in Blantyre, Malawi. Stroke 36(5), 960–964 (2005).
  • Rerkpattanapipat P, Wongpraparut N, Jacobs LE, Kotler MN. Cardiac manifestations of acquired immunodeficiency syndrome. Arch. Intern. Med. 160(5), 602–608 (2000).
  • De Rosa FG, Cicalini S, Canta F, Audagnotto S, Cecchi E, Di Perri G. Infective endocarditis in intravenous drug users from Italy: the increasing importance in HIV-infected patients. Infection 35(3), 154–160 (2007).
  • Miro JM, Del Rio A, Mestres CA. Infective endocarditis in intravenous drug abusers and HIV-1 infected patients. Infect. Dis. Clin. North Am. 16(2), 273–295, vii–viii (2002).
  • Lederman MM, Sereni D, Simonneau G, Voelkel NF. Pulmonary arterial hypertension and its association with HIV infection: an overview. AIDS 22( Suppl. 3), S1–S6 (2008).
  • Mette SA, Palevsky HI, Pietra GG et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am. Rev. Respir. Dis. 145(5), 1196–1200 (1992).
  • Ehrenreich H, Rieckmann P, Sinowatz F et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J. Immunol. 150(10), 4601–4609 (1993).
  • Mclaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 119(16), 2250–2294 (2009).
  • Degano B, Guillaume M, Savale L et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 24(1), 67–75 (2010).
  • Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS 22( Suppl. 3), S35–S40 (2008).
  • Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N. Engl. J. Med. 332(18), 1181–1185 (1995).
  • Stotka JL, Good CB, Downer WR, Kapoor WN. Pericardial effusion and tamponade due to Kaposi's sarcoma in acquired immunodeficiency syndrome. Chest 95(6), 1359–1361 (1989).
  • Little RF, Gutierrez M, Jaffe ES, Pau A, Horne M, Wilson W. HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis. JAMA 285(14), 1880–1885 (2001).
  • Lewis W. AIDS: cardiac findings from 115 autopsies. Prog. Cardiovasc. Dis. 32(3), 207–215 (1989).
  • Montalbetti L, Della Volpe A, Airaghi ML, Landoni C, Brambilla-Pisoni G, Pozzi S. Primary cardiac lymphoma. A case report and review. Minerva cardioangiol. 47(5), 175–182 (1999).
  • Sturm A, Noppeney R, Reimer J et al. [AIDS and non-Hodgkin's lymphoma: initial cardiac manifestations of highly malignant B-cell lymphoma 18 years after HIV infection]. Deutsch. Med. Wochenschr. 126(13), 364–366 (2001).
  • Sabin CA. HIV viremia and the development of AIDS-related lymphoma in patients treated with highly active antiretroviral therapy. J. Infect. Dis. 200(1), 8–10 (2009).
  • Clarke CA, Glaser SL. Epidemiologic trends in HIV-associated lymphomas. Curr. Opin. Oncol. 13(5), 354–359 (2001).
  • El-Sherif N, Turitto G. Torsade de pointes. Curr. Opin. Cardiol. 18(1), 6–13 (2003).
  • Passman R, Kadish A. Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. Med. Clin. North Am. 85(2), 321–341 (2001).
  • Kocheril AG, Bokhari SA, Batsford WP, Sinusas AJ. Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin. Electrophysiol. 20(11), 2810–2816 (1997).
  • Khunnawat C, Mukerji S, Havlichek D Jr, Touma R, Abela GS. Cardiovascular manifestations in human immunodeficiency virus-infected patients. Am. J. Cardiol. 102(5), 635–642 (2008).
  • Villa A, Foresti V, Confalonieri F. Autonomic neuropathy and prolongation of QT interval in human immunodeficiency virus infection. Clin. Auton. Res. 5(1), 48–52 (1995).
  • Anson BD, Weaver JG, Ackerman MJ et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 365(9460), 682–686 (2005).
  • Hsue PY, Squires K, Bolger AF et al. Screening and assessment of coronary heart disease in HIV-infected patients. Circulation 118(2), e41–e47 (2008).
  • Stein JH, Hadigan CM, Brown TT et al. Prevention strategies for cardiovascular disease in HIV-infected patients. Circulation 118(2), e54–60 (2008).
  • Dube MP, Stein JH, Aberg JA et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin. Infect. Dis. 37(5), 613–627 (2003).
  • National Cholesterol Education Program Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143–3421 (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.